Compare Boston Scientific Corporation (BSX) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Sea Limited — how do they compare? Boston Scientific Corporation trades at $43.06 (market cap $66.37B), while Sea Limited trades at $111.68 (market cap $66.94B). The key difference: Boston Scientific Corporation and Sea Limited are close in size by market cap, and Sea Limited is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | SE | |
|---|---|---|
Market Cap | $66.37B | $66.94B |
Sector | Health | Media |
52-Week High | $108.14 | $196.50 |
52-Week Low | $42.63 | $78.16 |
Enterprise Value | $75.94B | $59.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
SE trades at $110.66, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $22.94B in 2025, and improving profitability with a net income margin of 6.36%. Recent earnings beat expectations in Q1 2026, but insider sales have drawn media attention. Cash flow turned positive in 2025 at $2.34B, reflecting operational strength.
Outlook remains positive with a consensus price target of $131, implying 18% upside. Risks include competitive pressures in Southeast Asia and execution on growth investments. Analyst sentiment is strongly bullish with 70% buy ratings, though high valuation multiples and recent insider selling warrant caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
